The fall in deaths from hepatitis C in 2016 – the first in more than a decade – has continued into 2017. This is likely to be the result of increased treatment with new direct acting antiviral (DAA) drugs, with an increase of nearly 50 per cent over the last year, and of nearly 90 per cent when compared to earlier years.

Now that hepatitis C is much easier to treat, Public Health England is pushing to reduce its prevalence. A problem is that a substantial number of the estimated 214,000 people living with hep C infection may be unaware they have the virus.

Despite its debilitating effect on the liver – it can cause severe liver damage and cancer – many with hep C may have no specific symptoms, with some (including tiredness and abdominal pain) easily overlooked.

Around one-third of those with the long-term infection are believed to be aged over 50 years and may have contracted the virus years ago. Injecting drug use continues to be the most important risk factor for infection.

PHE is encouraging people to get tested and has drawn up a list of criteria for anyone who is concerned about whether they should get tested. GP practices, GUM clinics and drug treatment services can provide tests.

Originally Published by Pharmacy Magazine

Recommended

Interview: PSNC's Simon Dukes

Simon Dukes has taken on the toughest job in UK pharmacy and he’s going to need all his experience to sort out the...

Pharmacy organisations to meet with MPs

Representatives of the community pharmacy profession are hosting a Parliamentary briefing to highlight pharmacy's role i...




This website is for healthcare professionals only. By clicking "Accept" to hide this message or by clicking into any content on this website, you confirm you are a healthcare professional, consent to accepting cookies in accordance with our Cookie Policy and agree to British Pharmaceutical Students' Association’s Terms of Use and Privacy Policy.